Which has higher earnings and valuation, EQ or EIKN?

Equillium is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Equillium N/A N/A -$22.40M -$0.20 N/A Eikon Therapeutics N/A N/A -$324.25M -$4.09 N/A

Is EQ or EIKN more profitable?

Eikon Therapeutics' return on equity of 0.00% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -41.15% -38.29% Eikon Therapeutics N/A N/A N/A

Does the media prefer EQ or EIKN?

In the previous week, Eikon Therapeutics had 2 more articles in the media than Equillium. MarketBeat recorded 5 mentions for Eikon Therapeutics and 3 mentions for Equillium. Eikon Therapeutics' average media sentiment score of 0.67 beat Equillium's score of -0.28 indicating that Eikon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Eikon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is EQ or PRTA more profitable?

Equillium has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -41.15% -38.29% Prothena -80.68% -16.45% -14.51%

Does the media favor EQ or PRTA?

In the previous week, Prothena had 3 more articles in the media than Equillium. MarketBeat recorded 6 mentions for Prothena and 3 mentions for Equillium. Prothena's average media sentiment score of 1.18 beat Equillium's score of -0.28 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Prothena 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, EQ or KYTX?

Equillium is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Equillium N/A N/A -$22.40M -$0.20 N/A Kyverna Therapeutics N/A N/A -$161.31M -$2.94 N/A

Is EQ or KYTX more profitable?

Equillium's return on equity of -41.15% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -41.15% -38.29% Kyverna Therapeutics N/A -81.92% -63.74%

Does the media prefer EQ or KYTX?

In the previous week, Equillium had 2 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 3 mentions for Equillium and 1 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.00 beat Equillium's score of -0.28 indicating that Kyverna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Kyverna Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor EQ or EDIT?

In the previous week, Editas Medicine had 3 more articles in the media than Equillium. MarketBeat recorded 6 mentions for Editas Medicine and 3 mentions for Equillium. Editas Medicine's average media sentiment score of 0.37 beat Equillium's score of -0.28 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Editas Medicine 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is EQ or IRD more profitable?

Equillium has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Equillium's return on equity of -41.15% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -41.15% -38.29% Opus Genetics -1,091.82% -338.88% -150.13%

Equillium (EQ) Competitors

$1.75 -0.18 (-9.33%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.80 +0.05 (+2.86%)

As of 09/23/2026 07:55 PM Eastern

Compare

EQ vs. EIKN, PRTA, KYTX, EDIT, and IRD

Should you buy Equillium stock or one of its competitors? Equillium's main competitors and comparable companies include Eikon Therapeutics (EIKN), Prothena (PRTA), Kyverna Therapeutics (KYTX), Editas Medicine (EDIT), and Opus Genetics (IRD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Equillium compare to Eikon Therapeutics?

Equillium (NASDAQ:EQ) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

Equillium currently has a consensus target price of $7.57, indicating a potential upside of 332.65%. Eikon Therapeutics has a consensus target price of $25.00, indicating a potential upside of 207.50%. Given Equillium's stronger consensus rating and higher probable upside, analysts plainly believe Equillium is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Equillium is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	N/A	N/A	-$22.40M	-$0.20	N/A
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A

In the previous week, Eikon Therapeutics had 2 more articles in the media than Equillium. MarketBeat recorded 5 mentions for Eikon Therapeutics and 3 mentions for Equillium. Eikon Therapeutics' average media sentiment score of 0.67 beat Equillium's score of -0.28 indicating that Eikon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eikon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

27.0% of Equillium shares are held by institutional investors. 17.8% of Equillium shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Eikon Therapeutics' return on equity of 0.00% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-41.15%	-38.29%
Eikon Therapeutics	N/A	N/A	N/A

Summary

Equillium beats Eikon Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Equillium compare to Prothena?

Equillium (NASDAQ:EQ) and Prothena (NASDAQ:PRTA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

Equillium has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market. Comparatively, Prothena has a beta of -0.33, indicating that its share price is 133% less volatile than the broader market.

Equillium has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	N/A	N/A	-$22.40M	-$0.20	N/A
Prothena	$9.68M	46.94	-$244.09M	-$0.84	N/A

In the previous week, Prothena had 3 more articles in the media than Equillium. MarketBeat recorded 6 mentions for Prothena and 3 mentions for Equillium. Prothena's average media sentiment score of 1.18 beat Equillium's score of -0.28 indicating that Prothena is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prothena	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Equillium currently has a consensus target price of $7.57, indicating a potential upside of 332.65%. Prothena has a consensus target price of $24.57, indicating a potential upside of 183.08%. Given Equillium's stronger consensus rating and higher probable upside, equities research analysts plainly believe Equillium is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Equillium has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-41.15%	-38.29%
Prothena	-80.68%	-16.45%	-14.51%

27.0% of Equillium shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 17.8% of Equillium shares are held by company insiders. Comparatively, 10.4% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Equillium beats Prothena on 10 of the 16 factors compared between the two stocks.

How does Equillium compare to Kyverna Therapeutics?

Equillium (NASDAQ:EQ) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Equillium currently has a consensus price target of $7.57, suggesting a potential upside of 332.65%. Kyverna Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 324.33%. Given Equillium's stronger consensus rating and higher probable upside, equities research analysts plainly believe Equillium is more favorable than Kyverna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

27.0% of Equillium shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 17.8% of Equillium shares are held by insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Equillium is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	N/A	N/A	-$22.40M	-$0.20	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A

In the previous week, Equillium had 2 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 3 mentions for Equillium and 1 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.00 beat Equillium's score of -0.28 indicating that Kyverna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyverna Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Equillium has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market.

Equillium's return on equity of -41.15% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-41.15%	-38.29%
Kyverna Therapeutics	N/A	-81.92%	-63.74%

Summary

Equillium beats Kyverna Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Equillium compare to Editas Medicine?

Equillium (NASDAQ:EQ) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Equillium currently has a consensus target price of $7.57, indicating a potential upside of 332.65%. Editas Medicine has a consensus target price of $5.80, indicating a potential upside of 115.61%. Given Equillium's stronger consensus rating and higher possible upside, analysts clearly believe Equillium is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Equillium has a net margin of 0.00% compared to Editas Medicine's net margin of -157.32%. Equillium's return on equity of -41.15% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-41.15%	-38.29%
Editas Medicine	-157.32%	-196.63%	-38.17%

Equillium has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market.

27.0% of Equillium shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 17.8% of Equillium shares are owned by company insiders. Comparatively, 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Equillium has higher earnings, but lower revenue than Editas Medicine. Equillium is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	N/A	N/A	-$22.40M	-$0.20	N/A
Editas Medicine	$40.52M	10.20	-$160.06M	-$0.75	N/A

In the previous week, Editas Medicine had 3 more articles in the media than Equillium. MarketBeat recorded 6 mentions for Editas Medicine and 3 mentions for Equillium. Editas Medicine's average media sentiment score of 0.37 beat Equillium's score of -0.28 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Editas Medicine	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Equillium beats Editas Medicine on 9 of the 16 factors compared between the two stocks.

How does Equillium compare to Opus Genetics?

Equillium (NASDAQ:EQ) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

Equillium has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Equillium's return on equity of -41.15% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-41.15%	-38.29%
Opus Genetics	-1,091.82%	-338.88%	-150.13%

Equillium currently has a consensus target price of $7.57, indicating a potential upside of 332.65%. Opus Genetics has a consensus target price of $11.92, indicating a potential upside of 146.85%. Given Equillium's stronger consensus rating and higher probable upside, equities research analysts plainly believe Equillium is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Equillium had 3 more articles in the media than Opus Genetics. MarketBeat recorded 3 mentions for Equillium and 0 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 1.73 beat Equillium's score of -0.28 indicating that Opus Genetics is being referred to more favorably in the news media.

Company	Overall Sentiment
Equillium	Neutral
Opus Genetics	Very Positive

Equillium has higher earnings, but lower revenue than Opus Genetics. Equillium is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	N/A	N/A	-$22.40M	-$0.20	N/A
Opus Genetics	$14.20M	28.11	-$49.59M	-$1.35	N/A

27.0% of Equillium shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 17.8% of Equillium shares are held by company insiders. Comparatively, 11.7% of Opus Genetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Equillium has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

Summary

Equillium beats Opus Genetics on 12 of the 16 factors compared between the two stocks.

Get Equillium News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EQ vs. The Competition

Export

Metric	Equillium	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$122.38M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-8.75	13.88	274.08	25.69
Price / Sales	N/A	1,343.77	638.21	78.99
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	3.72	15.40	10.47	6.32
Net Income	-$22.40M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-7.41%	-1.70%	-0.67%	0.17%
1 Month Performance	-20.45%	-6.17%	-3.17%	-3.27%
1 Year Performance	21.53%	30.67%	15.14%	5.58%

Equillium Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EQ Equillium	2.3141 of 5 stars	$1.75 -9.3%	$7.57 +332.7%	+24.1%	$122.38M	N/A	N/A	14	Analyst Forecast
EIKN Eikon Therapeutics	3.293 of 5 stars	$8.98 +1.7%	$25.00 +178.4%	N/A	$478.28M	N/A	N/A	384
PRTA Prothena	3.3941 of 5 stars	$8.99 +5.6%	$24.57 +173.3%	+4.5%	$445.53M	$9.68M	N/A	67	Positive News Insider Trade Gap Up
KYTX Kyverna Therapeutics	1.4658 of 5 stars	$7.51 +5.5%	$30.00 +299.5%	+12.0%	$440.33M	N/A	N/A	149	News Coverage Analyst Forecast
EDIT Editas Medicine	2.5051 of 5 stars	$2.92 +3.2%	$6.00 +105.5%	-10.6%	$434.63M	$40.52M	N/A	87	News Coverage Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EQ) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Equillium (EQ) Competitors

EQ vs. EIKN, PRTA, KYTX, EDIT, and IRD

How does Equillium compare to Eikon Therapeutics?

Summary

How does Equillium compare to Prothena?

Summary

How does Equillium compare to Kyverna Therapeutics?

Summary

How does Equillium compare to Editas Medicine?

Summary

How does Equillium compare to Opus Genetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EQ vs. The Competition

Equillium Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Equillium (EQ) Competitors

EQ vs. EIKN, PRTA, KYTX, EDIT, and IRD

How does Equillium compare to Eikon Therapeutics?

Do analysts rate EQ or EIKN?

Which has higher earnings and valuation, EQ or EIKN?

Does the media prefer EQ or EIKN?

Do institutionals and insiders believe in EQ or EIKN?

Is EQ or EIKN more profitable?

Summary

How does Equillium compare to Prothena?

Which has more risk and volatility, EQ or PRTA?

Which has stronger earnings & valuation, EQ or PRTA?

Does the media favor EQ or PRTA?

Do analysts rate EQ or PRTA?

Is EQ or PRTA more profitable?

Do insiders & institutionals believe in EQ or PRTA?

Summary

How does Equillium compare to Kyverna Therapeutics?

Do analysts rate EQ or KYTX?

Do insiders & institutionals have more ownership in EQ or KYTX?

Which has better earnings & valuation, EQ or KYTX?

Does the media prefer EQ or KYTX?

Which has more volatility & risk, EQ or KYTX?

Is EQ or KYTX more profitable?

Summary

How does Equillium compare to Editas Medicine?

Do analysts recommend EQ or EDIT?

Is EQ or EDIT more profitable?

Which has more volatility & risk, EQ or EDIT?

Do insiders & institutionals believe in EQ or EDIT?

Which has stronger valuation & earnings, EQ or EDIT?

Does the media favor EQ or EDIT?

Summary

How does Equillium compare to Opus Genetics?

Is EQ or IRD more profitable?

Do analysts recommend EQ or IRD?

Does the media favor EQ or IRD?

Which has higher valuation and earnings, EQ or IRD?

Do institutionals & insiders believe in EQ or IRD?

Which has more risk & volatility, EQ or IRD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EQ vs. The Competition

Equillium Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools